Grant of Options
Updated : 07:05
27 March 2019
Surgical Innovations Group plc
("Surgical Innovations" or "the Company")
Grant of Options
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, announces that the Board has resolved to grant share options under the existing Enterprise Management Incentive scheme to acquire a maximum of 12,050,000 ordinary shares in the Company at an exercise price of 3.50 pence each, exercisable between 28 March 2022 and 27 March 2029 (the "Options").
The Options have been granted to a number of key personnel, including awards to PDMRs of 3,000,000 Options to Melanie Ross, Chief Financial Officer of the Company and 600,000 to Charmaine Day, Company Secretary. Following the grant of Options, the beneficial holding of Melanie Ross in the Company is 2,078,354 ordinary shares (representing 0.26% of the issued share capital) and 10,750,000 share options. David Marsh, CEO and Adam Power, Group Development Director have chosen to waive their option entitlement, as they are each already significant shareholders in the Company and seek to provide opportunities for other key management to increase their stake within the available headroom.
For further information contact:
Surgical Innovations Group Plc | |
Nigel Rogers, Non-Executive Chairman | Tel: +44 (0)113 230 7597 |
Melanie Ross, CFO |
|
|
|
Walbrook PR (Financial PR & Investor Relations) | Tel: +44 (0)20 7933 8780 or si@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 |
|
|
N+1 Singer (Nominated Adviser and Broker) | +44 (0)20 7496 3000 |
Richard Lindley |
|
Rachel Hayes |
|
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Melanie Ross | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer, Surgical Innovations Group plc | ||||
b) | Initial notification/ Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Surgical Innovations Group plc | ||||
b) | LEI | 2138004GHGUH3HUZE156 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1p
GB0004016704 | ||||
b) | Nature of the transactions | Grant of options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||||
e) | Date of the transaction | 26 March 2019 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Charmaine Day | ||||
2 | Reason for the notification | |||||
a) | Position/status | Company Secretary, Surgical Innovations Group plc | ||||
b) | Initial notification/ Amendment | Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Surgical Innovations Group plc | ||||
b) | LEI | 2138004GHGUH3HUZE156 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1p
GB0004016704 | ||||
b) | Nature of the transactions | Grant of options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A N/A | ||||
e) | Date of the transaction | 26 March 2019 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.